Covid test frenzy is windfall for delivery services, and their drivers

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 51 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 51%

Health Health Headlines News

Surging demand for Covid-19 tests has been a windfall for delivery apps like Gopuff, DoorDash, and FastAF. One driver sees tips jump by more than 500%.

Some drivers say tips have gone up more than 500% because order values are up.The current Covid-19 surge has been a boon for fast delivery services like Gopuff, DoorDash, and FastAF, as consumers rush to order test kits and many people avoid public places all over again.

Delivery drivers say they've also experienced a mini-windfall in tips as they ferry boxes of tests to grateful customers. This is a rare moment in the gig economy where customer demand is benefitting both the companies and their fleets of contract workers. Drivers and company executives at the delivery startups mostly chalk up the increased tips to the fact that these test kits bump up the overall value of each order delivered. For example, the typical Gopuff order is for around $23, according to data from. That's the same cost for a single On/Go Covid-19 test kit box on the app—meaning adding just one kit to the average order already doubles its value.

FastAF focuses on higher end goods and already has higher order values, averaging around $140. That already translates into better tips for drivers. Still, Hnetinka, the CEO, says the average tip value for orders with Covid-19 tests has been around $9. One driver had a $101 in tip on single order that had Covid tests, he said.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 729. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA acts to expand use of treatment for COVID-19 patients with mild-to-moderate diseasePreviously, the use of Veklury, a Gilead Sciences Inc. drug, was limited to those requiring hospitalization.
Source: FOX29philly - 🏆 570. / 51 Read more »